Ignite Creation Date:
2024-05-06 @ 3:43 PM
Last Modification Date:
2024-10-26 @ 1:55 PM
Study NCT ID:
NCT04732650
Status:
NOT_YET_RECRUITING
Last Update Posted:
2021-02-01
First Post:
2020-12-10
Brief Title:
Real World Difference After Changing Medication From Nonselective to Selective Endothelin Receptor Antagonist in Stable Eisenmenger Syndrome
Sponsor:
Samsung Medical Center
Organization:
Samsung Medical Center
Study Overview
Official Title:
Real World Difference After Changing Medication From Nonselective to Selective Endothelin Receptor Antagonist in Stable Eisenmenger Syndrome Observational Study
Status:
NOT_YET_RECRUITING
Status Verified Date:
2021-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
In this study the investigator will evaluate the treatment effects and safety patient compliance of Ambrisentan in Eisenmenger syndrome in PAH patients who have been previously treated with Bosentan
Detailed Description:
Endothelin receptor antagonist is an established class of targeted therapy for pulmonary arterial hypertension PAH Nonselective ERA Bosentan was the first approved ERA for PAH Selective ERA Ambrisentan was also approved for PAH treatment consequently Although non-selective and selective ERA are both effective in clinical trials there is no direct comparison for non-selective and selective ERA Furthermore approval study for both non-selective and selective ERA did not include the PAH associated with congenital heart disease PAH-CHD with significant shunt including Eisenmenger syndrome Approval study for AmbrisentanARIES-1 and ARIES-2 trials also did not include the PAH-CHD In Korea Bosentan was approved in 2003 and Ambrisentan was approved in 2009 for idiopathic PAH Bosentan was also approved for PAH-CHD however Amrisentan was not because of limited data for PAH-CHD Therefore Bosentan was the only ERA covered by public health insurance since 2018 for PAH-CHD Recently Amrisentan was also approved for PAH associated with congenital heart disease including Eisenmger syndrome And there is a need for changing medication from double pill medication to once-daily dose medication because of patients compliance
PAH associated with CHD includes the group with significant shunt vs without shunt sp corrected state When there is a shunt flow change in pulmonary vascular resistance PVR and cardiac output can be a modulator of shunt flow thus impact of pulmonary vasodilator on hemodynamics can be different from PAH without shunt However there is a limited data for changing ERA from non-selective to selective ERA Our patients population can be interesting study group to understand the clinical response to changing between ERA because they are uniformly treated with non-selective ERA to selective ERA Bosentan to Ambrisentan
In this study the investigators will evaluate the treatment effects and safety patient compliance of Ambrisentan in Eisenmenger syndrome in PAH patients who have been previously treated with Bosentan
PAH associated with CHD includes the group with significant shunt vs without shunt sp corrected state When there is a shunt flow change in pulmonary vascular resistance PVR and cardiac output can be a modulator of shunt flow thus impact of pulmonary vasodilator on hemodynamics can be different from PAH without shunt However there is a limited data for changing ERA from non-selective to selective ERA Our patients population can be interesting study group to understand the clinical response to changing between ERA because they are uniformly treated with non-selective ERA to selective ERA Bosentan to Ambrisentan
In this study the investigators will evaluate the treatment effects and safety patient compliance of Ambrisentan in Eisenmenger syndrome in PAH patients who have been previously treated with Bosentan
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None